Trials / Completed
CompletedNCT04252833
Open-label, Crossover, Food Effect Study to Evaluate CT-044 in Healthy Human Volunteers
Open-label, Crossover, Food Effect Study to Evaluate the Single Dose Pharmacokinetics of CT-044, a Reactive Species Decomposition Accelerant, in Healthy Human Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Lotus Clinical Research, LLC · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This open-label study will be conducted to assess the bioavailability and PK of oral single doses of CT-044 following administration with and without food and to evaluate the safety and tolerability of CT-044 when given with and without food.
Detailed description
The food effect study will be an open-label, 2-sequence, balanced crossover design in 12 subjects previously untreated with CT-044. Eligible subjects will be admitted to the Clinical Trial Unit on the day prior to dosing and remain in house until Day 3. Each subject will receive CT-044 single oral dose once under fed conditions (i.e., a high fat meal per FDA recommendations) and once in the fasted state. 9 Subjects will return to the Clinical Trial Unit on an outpatient basis for follow-up. Subjects will return to the Clinical Trial Unit to be treated by the second sequence after a washout period of at least 7 days, but no more than 14 days. All procedures will be repeated for the second treatment sequence. When possible, the procedures conducted at the 144-hour follow-up visit for the first sequence may serve as baseline for the second sequence of the crossover.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CT-044 | CT-044 HCl is a reactive species decomposition accelerant |
Timeline
- Start date
- 2020-02-18
- Primary completion
- 2020-03-16
- Completion
- 2020-03-16
- First posted
- 2020-02-05
- Last updated
- 2020-06-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04252833. Inclusion in this directory is not an endorsement.